Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

NADIS NAD+ International Scientist-training

Coordinator
Stichting Amsterdam Umc, Netherlands
Runs
1 November 2022 to 31 October 2026
Status
Running
EU funding
€2.5m
Total cost
—
Partners
21 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101073251

What the project is doing

In the project's own words, from its summary on CORDIS.

Nicotinamide adenine dinucleotide (NAD+) is a central redox cofactor and the limiting substrate of key metabolic enzymes. The constellation of cellular functions in which NAD+ is involved makes its availability critical for cell survival, and its depletion is a leading factor in a number of diseases in humans, ranging from rare inherited defects to more common multifactorial, often age-related, complications, including type 2 diabetes, neurodegenerative diseases and female infertility.

In contrast, NAD+-repletion strategies, such as administration of NAD+ precursors, may be effective in preventing or ameliorating the outcomes of these complications. NADIS partners have made pivotal discoveries in the field of NAD+ biology. First, by discovering novel mechanisms linking NAD+ metabolism to prevalent diseases such as type 2 diabetes, cancer cachexia, Alzheimer’s, Parkinson’s, or rare inherited mitochondrial disease, and to lifespan regulation.

Second, by identifying lifestyle, nutritional, and drug interventions that target NAD+ metabolic pathways to combat such diseases and promote healthy aging. Despite these recent advances, there are still major gaps in our current knowledge in regard to (1) how NAD+ homeostasis is regulated at different stages in life, (2) how its imbalance leads to disease at a systemic level and (3) which NAD+ repletion strategy is the most suitable to prevent or treat specific diseases.

It is the ambition of the NADIS consortium to fill these gaps by training the new generation of Early Stage Researchers (ESRs) on how to apply state-of-the-art tools to study the interconnection between metabolic cofactors, such as NAD+, and metabolic health at different levels, and to provide them with an interdisciplinary and intersectoral training programme that significantly increases their career perspectives and allow them to become future leaders in the field of translational metabolism.

Who is involved

OrganisationCityCountryRole
Stichting Amsterdam UmcAmsterdamNetherlandsCoordinator
Ecole Polytechnique Federale De LausanneLausanneSwitzerlandAssociatedpartner
Societe Des Produits Nestle SAVeveySwitzerlandAssociatedpartner
Deutsches Zentrum Fur Neurodegenerative Erkrankungen eVBonnGermanyParticipant
Eberhard Karls Universitaet TuebingenTuebingenGermanyAssociatedpartner
Gesellschaft zur Förderung der Lebenswissenschaften Heidelberg GmbHHeidelbergGermanyAssociatedpartner
Saso KocevarHeidelbergGermanyAssociatedpartner
Sonja NossWiesbadenGermanyAssociatedpartner
Kobenhavns UniversitetKobenhavnDenmarkParticipant
Tracked.bioCopenhagen NDenmarkAssociatedpartner
Fundacion Universitaria San AntonioMurciaSpainAssociatedpartner
Oulun YliopistoOuluFinlandParticipant
Imagine Institut Des Maladies Genetiques Necker Enfants Malades FondationParisFranceParticipant
Universite Paris CiteParisFranceAssociatedpartner
Universita Degli Studi Di GenovaGenovaItalyParticipant
Khondrion BVBeuningenNetherlandsAssociatedpartner
Khondrion BVBeuningenNetherlandsParticipant
Stichting Hogeschool Van AmsterdamAmsterdamNetherlandsAssociatedpartner
Stichting Radboud UniversiteitNijmegenNetherlandsAssociatedpartner
Universiteit Van AmsterdamAmsterdamNetherlandsAssociatedpartner
Universitetet I OsloOsloNorwayParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI